A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes
- A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes. Mann, J. F. // Evidence Based Medicine;Feb2009, Vol. 14 Issue 1, p3
The article presents a study titled "A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes". The study used randomized controlled trial, the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARTGET). The study...
- Peripheral Arterial Disease in People With Diabetes:
Consensus Statement Recommends Screening. Sheehan, Peter // Clinical Diabetes;Fall2004, Vol. 22 Issue 4, p179
Provides information on peripheral arterial disease (PAD) in people with diabetes. Issues concerning PAD and diabetes; Biology of PAD in diabetes; Goals of treatment for patients diagnosed with PAD.
- Recent US Patterns and Predictors of Prevalent Diabetes among Acute Myocardial Infarction Patients. Ovbiagele, Bruce; Markovic, Daniela; Fonarow, Gregg C. // Cardiology Research & Practice;2011, p1
Background. Diabetes mellitus (DM) confers high vascular risk and is a growing national epidemic. We assessed clinical characteristics and prevalence of diagnosed DM among patients hospitalized with acute myocardial infarction (AMI) in the US over the last decade. Methods. Data were obtained...
- THE IMPACT OF THE HOPE AND MICRO-HOPE STUDIES IN THE DIABETIC CLINIC. // Heart;May2001 Supplement 1, Vol. 85, pP5
The article focuses on the impact of the HOPE and MICRO-HOPE studies in the diabetic clinic. The recent HOPE and MICRO-HOPE studies have indicated a substantial reduction in vascular events and nephropathy in patients with documented vascular disease or diabetes and one other risk factor who are...
- Peripheral Artery Disease: Helping Patients to Walk the Walk. // Critical Care Alert;Apr2013 Clincal Briefs in Primary Care, p1
The article reports a study conducted which revealed that inhibition of angiotensin-converting enzyme (ACE) with ramipril as an adjunct to standard medical therapy increases both the maximum and the pain-free walking time of patients with peripheral artery disease (PAD).
- Peripheral Artery Disease: Helping Patients to Walk the Walk. // Hospital Medicine Alert;Apr2013 Clinical Briefs in Primary Care, p7
The article discusses treatment options for peripheral artery disease (PAD), including the use of angiotensin-converting enzyme (ACE) inhibitor ramipril that improved walking time in patients as well as the implied risk of cardiovascular disease for patients with PAD.
- Peripheral Artery Disease: Helping Patients to Walk the Walk. // OB/GYN Clinical Alert;Apr2013 Clinical Bries in Primary Care, p1
The article discusses a study conducted by researcher A. A. Ahimastos and colleagues which reveals the importance of pharmacotherapy in the treatment of patients with peripheral artery disease (PAD).
- Peripheral Artery Disease: Helping Patients to Walk the Walk. Kuritzky, Louis // Clinical Cardiology Alert;Apr2013 Clinical Briefs in Primary Care, p7
The article reports a study which found that in patients with peripheral artery disease (PAD), 6-month treatment of ramipril resulted in significant increases in pain-free walking time.
- Factors that impact on the application of guidelines in general practice: a review of medical records and structured investigation of clinical incidents in hypertension. Jiwa, Moyez; Freeman, Jennifer; Fisher, Claire; Schrecker, Geoff; Gordon, Michael; Reid, John // Quality in Primary Care;2005, Vol. 13 Issue 4, p213
Introduction The management of hypertension in the older individual is complicated by the need to take into account the effect of the ageing process. However, older hypertensive patients are at higher risk of vascular disease, and therapy may be more cost-effective in this age group. Methods A...